Who are teriparatide and raloxifene's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/teriparatide-and-raloxifene.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

teriparatide and raloxifene — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

teriparatide and raloxifene (teriparatide and raloxifene) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: PTH analog and selective estrogen receptor modulator (SERM). Area: Endocrinology / Bone Metabolism.

marketed Combination therapy: PTH analog and selective estrogen receptor modulator (SERM) PTH1 receptor (teriparatide); estrogen receptor alpha and beta (raloxifene) Endocrinology / Bone Metabolism Small molecule Live · refreshed every 30 min

Target snapshot

teriparatide and raloxifene (teriparatide and raloxifene) — Medical University of Vienna. This combination therapy stimulates bone formation through PTH receptor activation while simultaneously blocking estrogen receptor-mediated bone resorption.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
teriparatide and raloxifene TARGET	teriparatide and raloxifene	Medical University of Vienna	marketed	Combination therapy: PTH analog and selective estrogen receptor modulator (SERM)	PTH1 receptor (teriparatide); estrogen receptor alpha and beta (raloxifene)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: PTH analog and selective estrogen receptor modulator (SERM) class)

Medical University of Vienna · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). teriparatide and raloxifene — Competitive Intelligence Brief. https://druglandscape.com/ci/teriparatide-and-raloxifene. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab